A detailed history of Ubs Group Ag transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 200,726 shares of MCRB stock, worth $164,595. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200,726
Previous 105,966 89.42%
Holding current value
$164,595
Previous $81,000 77.78%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.56 - $1.19 $53,065 - $112,764
94,760 Added 89.42%
200,726 $144,000
Q1 2024

May 13, 2024

BUY
$0.75 - $1.56 $73,437 - $152,748
97,916 Added 1216.35%
105,966 $81,000
Q4 2023

Feb 09, 2024

SELL
$0.93 - $2.15 $147,020 - $339,887
-158,087 Reduced 95.15%
8,050 $11,000
Q3 2023

Nov 09, 2023

BUY
$2.33 - $5.07 $216,470 - $471,033
92,906 Added 126.87%
166,137 $395,000
Q2 2023

Aug 11, 2023

SELL
$4.67 - $6.55 $172,192 - $241,511
-36,872 Reduced 33.49%
73,231 $350,000
Q1 2023

May 12, 2023

SELL
$4.95 - $6.09 $550,172 - $676,879
-111,146 Reduced 50.24%
110,103 $624,000
Q4 2022

Feb 08, 2023

BUY
$5.09 - $9.05 $944,072 - $1.68 Million
185,476 Added 518.48%
221,249 $1.24 Million
Q3 2022

Nov 10, 2022

BUY
$3.5 - $7.2 $112,528 - $231,487
32,151 Added 887.66%
35,773 $229,000
Q2 2022

Aug 10, 2022

SELL
$2.7 - $7.62 $243,486 - $687,171
-90,180 Reduced 96.14%
3,622 $12,000
Q1 2022

May 16, 2022

BUY
$6.3 - $8.84 $561,600 - $788,024
89,143 Added 1913.35%
93,802 $668,000
Q4 2021

Feb 14, 2022

SELL
$6.02 - $11.43 $2.36 Million - $4.47 Million
-391,204 Reduced 98.82%
4,659 $39,000
Q3 2021

Nov 15, 2021

BUY
$5.46 - $22.6 $2.12 Million - $8.77 Million
387,885 Added 4861.93%
395,863 $2.76 Million
Q2 2021

Aug 13, 2021

SELL
$18.46 - $24.36 $4,061 - $5,359
-220 Reduced 2.68%
7,978 $190,000
Q1 2021

May 12, 2021

BUY
$17.66 - $28.92 $112,988 - $185,030
6,398 Added 355.44%
8,198 $168,000
Q4 2020

Feb 11, 2021

SELL
$23.25 - $37.73 $167,237 - $271,391
-7,193 Reduced 79.98%
1,800 $44,000
Q3 2020

Nov 12, 2020

BUY
$3.74 - $28.74 $31,015 - $238,340
8,293 Added 1184.71%
8,993 $255,000
Q2 2020

Jul 31, 2020

SELL
$3.04 - $6.2 $35,972 - $73,364
-11,833 Reduced 94.41%
700 $3,000
Q1 2020

May 01, 2020

SELL
$2.64 - $3.82 $73,455 - $106,287
-27,824 Reduced 68.94%
12,533 $45,000
Q4 2019

Feb 14, 2020

BUY
$2.99 - $4.42 $54,570 - $80,669
18,251 Added 82.56%
40,357 $139,000
Q3 2019

Nov 14, 2019

BUY
$2.29 - $4.16 $47,645 - $86,552
20,806 Added 1600.46%
22,106 $88,000
Q2 2019

Aug 14, 2019

SELL
$2.28 - $7.35 $1,595 - $5,145
-700 Reduced 35.0%
1,300 $4,000
Q1 2019

May 14, 2019

SELL
$4.83 - $7.21 $5,675 - $8,471
-1,175 Reduced 37.01%
2,000 $14,000
Q4 2018

Feb 14, 2019

BUY
$4.52 - $8.88 $10,734 - $21,090
2,375 Added 296.88%
3,175 $15,000
Q3 2018

Nov 14, 2018

SELL
$7.33 - $9.23 $14,660 - $18,460
-2,000 Reduced 71.43%
800 $6,000
Q2 2018

Aug 14, 2018

BUY
$6.91 - $9.55 $4,837 - $6,685
700 Added 33.33%
2,800 $24,000
Q1 2018

May 15, 2018

SELL
$7.34 - $11.16 $3,670 - $5,580
-500 Reduced 19.23%
2,100 $15,000
Q3 2017

Nov 14, 2017

SELL
$12.81 - $16.85 $31,871 - $41,922
-2,488 Reduced 48.9%
2,600 $42,000
Q2 2017

Aug 14, 2017

SELL
N/A
-260 Reduced 4.86%
5,088 $57,000
Q1 2017

Nov 14, 2017

BUY
N/A
5,348
5,348 $60,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $102M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.